How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
9
BCYC Quote, Financials, Valuation and Earnings
Last price:
$14.60
Seasonality move
:
5.44%
Day range:
$14.56 - $15.10
52-week range:
$12.17 - $28.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.38x
P/B ratio:
1.21x
Volume:
170.8K
Avg. volume:
750.2K
1-year change:
-21.55%
Market cap:
$1B
Revenue:
$27M
EPS (TTM):
-$3.29
Analysts' Opinion
-
Consensus RatingBicycle Therapeutics PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.36, Bicycle Therapeutics PLC has an estimated upside of 128.52% from its current price of $14.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $14.60.
Fair Value
-
According to the consensus of 8 analysts, Bicycle Therapeutics PLC has 128.52% upside to fair value with a price target of $33.36 per share.
BCYC vs. S&P 500
-
Over the past 5 trading days, Bicycle Therapeutics PLC has underperformed the S&P 500 by -6.35% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bicycle Therapeutics PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bicycle Therapeutics PLC revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bicycle Therapeutics PLC reported revenues of $2.7M.
Earnings Growth
-
Bicycle Therapeutics PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bicycle Therapeutics PLC reported earnings per share of -$0.74.
Enterprise value:
117.2M
EV / Invested capital:
0.14x
Price / LTM sales:
20.38x
EV / EBIT:
--
EV / Revenue:
3.18x
PEG ratio (5yr expected):
-0.78x
EV / Free cash flow:
-0.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-21.68%
Net Income Margin (TTM):
-450.64%
Return On Equity:
-29.19%
Return On Invested Capital:
-27.99%
Operating Margin:
-2373.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $15M | $24.8M | $36.9M | $5.4M | $2.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$101.8M | -$167.2M | -$196.5M | -$50.1M | -$63.5M | |
| EBITDA | -$96.6M | -$151.3M | -$160M | -$45.1M | -$52M | |
| Diluted EPS | -$3.42 | -$4.98 | -$3.29 | -$1.26 | -$0.74 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $164.2M | $272.9M | $381.3M | $603M | $966.2M | |
| Total Assets | $170.1M | $281.3M | $417.1M | $638.7M | $996.7M | |
| Current Liabilities | $17M | $30.2M | $41.6M | $69.7M | $56.4M | |
| Total Liabilities | $60.5M | $110.5M | $127.7M | $222.7M | $165.7M | |
| Total Equity | $109.6M | $170.8M | $289.5M | $416M | $831M | |
| Total Debt | $14.4M | $29.8M | $30.2M | $30.6M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$66.2M | -$43.6M | -$202.6M | -$1M | -$39.8M | |
| Cash From Investing | -$18.6M | -$4.3M | -$918K | -$502K | -$435K | |
| Cash From Financing | $191.5M | $255.5M | $519.9M | $234.6M | -$31.9M | |
| Free Cash Flow | -$84.8M | -$48M | -$203.5M | -$1.5M | -$40.3M | |
BCYC
Sector
Market Cap
$1B
$46.1M
Price % of 52-Week High
50.92%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-34.45%
-0.6%
1-Year Price Total Return
-21.55%
-30.52%
Beta (5-Year)
0.858
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$14.89
200-day SMA
Sell
Level
$22.62
Bollinger Bands (100)
Sell
Level
19.23 - 25.49
Chaikin Money Flow
Sell
Level
-5.6M
20-day SMA
Sell
Level
$17.75
Relative Strength Index (RSI14)
Sell
Level
28.49
ADX Line
Sell
Level
28.39
Williams %R
Neutral
Level
-73.9586
50-day SMA
Sell
Level
$21.24
MACD (12, 26)
Sell
Level
-1.96
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
8.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9101)
Sell
CA Score
(Annual)
Level (-1.3885)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.0323)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Stock Forecast FAQ
In the current month, BCYC has received 5 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BCYC average analyst price target in the past 3 months is $33.36.
-
Where Will Bicycle Therapeutics PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bicycle Therapeutics PLC share price will rise to $33.36 per share over the next 12 months.
-
What Do Analysts Say About Bicycle Therapeutics PLC?
Analysts are divided on their view about Bicycle Therapeutics PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bicycle Therapeutics PLC is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Bicycle Therapeutics PLC's Price Target?
The price target for Bicycle Therapeutics PLC over the next 1-year time period is forecast to be $33.36 according to 8 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BCYC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bicycle Therapeutics PLC is a Buy. 5 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BCYC?
You can purchase shares of Bicycle Therapeutics PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bicycle Therapeutics PLC shares.
-
What Is The Bicycle Therapeutics PLC Share Price Today?
Bicycle Therapeutics PLC was last trading at $14.60 per share. This represents the most recent stock quote for Bicycle Therapeutics PLC. Yesterday, Bicycle Therapeutics PLC closed at $14.60 per share.
-
How To Buy Bicycle Therapeutics PLC Stock Online?
In order to purchase Bicycle Therapeutics PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
